[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601240":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":53,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The Affiliated Hospital of Qingdao University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I (CKD stages 1-3)",null,"eGFR ≥ 30 mL\u002Fmin\u002F1.73 m²",[13],"Other: 18F PET\u002FMR",{"label":15,"type":10,"description":16,"interventionNames":17},"Group II (CKD stages 4-5)","eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"18F PET\u002FMR","Tracer: \\^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq\u002Fkg is administered.\n\n• Simultaneous PET\u002FMR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds.\n\n1. Cardiac Morphology and Function (Localization \\& Cine):Assess cardiac structure and global\u002Fregional function\n2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema\n3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects\n4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis\n5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis\n6. T2 Mapping (Pre Contrast):Quantify myocardial edema\n7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \\^18F FAPI PET data",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Pei Nie","PRINCIPAL_INVESTIGATOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Pei Nie, MD","CONTACT","+86 0532-821592","niepei@qdu.edu.cn",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Qingdao","Shandong","266003","China","CN",{"type":42,"coordinates":43},"Point",[44,45],120.38042,36.06488,{"lat":45,"lon":44},[48],{"name":29,"role":30,"phone":10,"phoneExt":10,"email":32},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100601240","multimodal-imaging-assessment-of-chronic-kidney-disease-patients-at-different-stages-from-a-cardio-renal-interaction-perspective-100601240",false,"NCT07107919","Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective","Inclusion Criteria:\n\n1. Age between 18 and 80 years, regardless of sex.\n2. Clinically diagnosed with chronic kidney disease (CKD), based on KDIGO guidelines.\n3. Complete clinical data available.\n4. Written informed consent for participation and for undergoing 18F-FAPI PET\u002FMR imaging is obtained from the patient or their legal guardian.\n5. Female participants must agree to use effective contraception during the study and for at least 6 months after its completion (e.g., sterilization, intrauterine hormonal devices, condoms, hormonal contraceptives, abstinence, or vasectomized partner). Male participants must also agree to use contraception during the study and for 6 months after its completion.\n\nExclusion Criteria:\n\n1. Women who are planning to conceive, currently pregnant, or breastfeeding.\n2. Contraindications to PET\u002FMR imaging, including but not limited to metal implants, claustrophobia, or inability to tolerate cardiac MRI due to respiratory difficulties.\n3. History of allergy or hypersensitivity to gadolinium-based contrast agents.\n4. Presence of malignant tumors or other serious progressive diseases.\n5. Patients with severe cardiac conditions, such as advanced heart failure, severe valvular disease, or cardiomyopathies.\n6. Hemodynamic instability.\n7. Presence of severe systemic or localized infections, or other serious comorbid conditions.\n8. Incomplete clinical data.\n9. Any other reason deemed by the investigators to make the subject unsuitable for participation, including inability or unwillingness to comply with study procedures and requirements.\n10. Determined by the investigators to be inappropriate for inclusion in the study.","ALL","18 Years","80 Years",{"count":61,"type":62},60,"ESTIMATED","OBSERVATIONAL","This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET\u002FMR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL\u002Fmin\u002F1.73 m²）,Group II :CKD stages 4-5(eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n\nUsing 18F-FAPI PET\u002FMR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.",[66,67,68],"Chronic Kidney Disease","Cardiac Magnetic Resonance","18F-FAPI",[70,67,68],"CKD","2025-07-31",{"date":73,"type":74},"2025-08-06","ACTUAL",{"date":76,"type":62},"2025-07-30",{"date":78,"type":62},"2027-06-01",{"name":5,"class":6},1]